CocrystalPharmaInc.jpg
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
06 août 2020 08h05 HE | Cocrystal Pharma, Inc.
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviralagents progresses – ...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces the Publication by Collaborators of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus in Science Translational Medicine Journal
04 août 2020 08h05 HE | Cocrystal Pharma, Inc.
– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication – – Cocrystal is currently further conducting preclinical studies of these coronavirus...
CocrystalPharmaInc.jpg
Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
14 mai 2020 07h05 HE | Cocrystal Pharma, Inc.
- Company has sufficient capital to advance pipeline and fund operations through 2021 - BOTHELL, WA, May 14, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the...
CocrystalPharmaInc.jpg
Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action
22 avr. 2020 08h05 HE | Cocrystal Pharma, Inc.
- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program - - Small molecule therapeutic inhibitors against coronaviruses included in agreement have...
CocrystalPharmaInc.jpg
Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020
30 mars 2020 06h05 HE | Cocrystal Pharma, Inc.
Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
CocrystalPharmaInc.jpg
Cocrystal Pharma Announces Plans to Advance Coronavirus Program
06 mars 2020 16h01 HE | Cocrystal Pharma, Inc.
Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial position bolsters Company’s...